Semaglutide and Pregnancy: What Patients Need to Know Before Trying to Conceive

If you are taking semaglutide for weight management or type 2 diabetes and are thinking about becoming pregnant, this is one of the most important conversations you can have with your doctor — and it needs to happen before you conceive, not after.

Semaglutide, like all GLP-1 receptor agonists, carries specific guidance around pregnancy that patients should understand clearly. The prescribing information for both Wegovy (semaglutide for weight management) and Ozempic (semaglutide for type 2 diabetes) includes explicit warnings about use during pregnancy.

This is not a topic where internet forums or social media advice will suffice. Pregnancy planning while on any prescription medication requires direct, personalised medical guidance. This article lays out the key facts so you can walk into that conversation informed — but it does not replace that conversation.

The official prescribing information for semaglutide-based products is clear: semaglutide should be discontinued before a planned pregnancy. The labels classify semaglutide with a warning based on animal reproduction studies, which showed adverse effects on embryo-foetal development.

Specifically:

• Animal studies conducted with semaglutide showed evidence of structural abnormalities (birth defects), growth retardation, and pregnancy loss at doses that are clinically relevant. These studies were conducted in rats and rabbits.
• No adequate human studies exist. There are no well-controlled clinical trials of semaglutide in pregnant women. The available data is insufficient to determine whether semaglutide poses a risk to human pregnancies.
• The recommendation from both the FDA-approved label and guidance adopted by the DCGI (Drug Controller General of India) for imported formulations is to avoid semaglutide during pregnancy.

This means the current medical consensus is precautionary: because the animal data raises concern and there is no human safety data to offset that concern, the medication should not be used during pregnancy.

One of the most practical questions patients ask is: how far in advance should I stop semaglutide before trying to conceive?

The prescribing information for Wegovy recommends discontinuing semaglutide at least 2 months before a planned pregnancy. This recommendation is based on semaglutide's long half-life — approximately 7 days for the injectable formulation. A 2-month washout allows the drug to be substantially cleared from the body before conception occurs.

Key points about this washout:

• Do not stop abruptly without medical guidance. Your doctor may want to adjust your dose gradually or transition you to a different weight management or diabetes strategy during this period.
• The 2-month window is a minimum. Depending on your individual health profile, your doctor may recommend a longer period, particularly if you are on higher doses.
• Contraception during the washout. If you are sexually active and have stopped semaglutide with the intention of conceiving, discuss contraception timing carefully with your physician to ensure the washout is complete before conception.

In India, where access to specific formulations may vary, your prescribing physician should confirm the exact washout guidance applicable to the product you are using — whether it is a branded import, a licensed generic, or another formulation.

A related question many patients have is whether semaglutide affects fertility itself — the ability to conceive, separate from its safety during pregnancy.

Here is what the current evidence shows:

• Weight loss can improve fertility. For patients with obesity-related conditions such as polycystic ovary syndrome (PCOS) or anovulation, losing weight — through any means — has been shown to improve ovulation and fertility outcomes. Some patients on GLP-1 medicines may experience improved fertility as a secondary effect of weight loss.
• This can create an unexpected pregnancy risk. If your menstrual cycles were previously irregular due to excess weight and they become more regular as you lose weight on semaglutide, your fertility may increase even before you actively plan for pregnancy. This is sometimes called the "Ozempic baby" phenomenon in popular media — though the mechanism is weight-loss-mediated, not a direct drug effect.
• Direct effects on fertility are not well-studied. There is limited data on whether semaglutide has a direct positive or negative effect on human fertility independent of weight change. Animal studies have shown some effects on reproductive organs, but these do not translate directly to humans.

The practical takeaway: if you are of reproductive age and on semaglutide, use reliable contraception unless you are actively planning a pregnancy under medical supervision. Do not assume that previous infertility or irregular cycles will continue unchanged while on this medication.

The question of whether semaglutide is safe during breastfeeding is another area where data is limited.

What the prescribing information states:

• It is not known whether semaglutide is excreted in human breast milk. Animal studies have shown that semaglutide-related compounds are present in the milk of lactating rats, but this does not confirm the same for humans.
• A risk to the breastfed infant cannot be excluded. Because of this uncertainty, the label recommends that the decision to breastfeed while on semaglutide should involve a careful discussion between the patient and their physician, weighing the benefits of breastfeeding against the potential risks of drug exposure.

In practice, most clinicians will recommend:

• Discontinuing semaglutide if you plan to breastfeed, at least until more safety data becomes available.
• Discussing alternative weight management or diabetes strategies that are considered compatible with breastfeeding.
• Monitoring both maternal and infant health closely if any medication is continued during the postpartum period.

This is an area where individual risk-benefit analysis is essential. There is no one-size-fits-all answer, and your treating physician is the right person to guide this decision.

Despite best planning, unplanned pregnancies happen. If you discover you are pregnant while currently taking semaglutide, here is what you should do:

• Stop the medication and contact your doctor immediately. Do not wait for your next scheduled appointment. Call your prescribing physician or care team as soon as possible.
• Do not panic. The animal data that informs the pregnancy warning involved sustained exposure at specific doses. A brief period of early exposure does not automatically mean harm has occurred. However, it does require prompt medical evaluation.
• Your doctor will assess your specific situation. They will consider how far along the pregnancy is, how long you were exposed, and what monitoring or specialist referrals may be appropriate.
• Do not make decisions based on internet forums. Every pregnancy is different. The risk assessment for your specific case should come from a qualified obstetrician or maternal-foetal medicine specialist, not from anonymous online advice.

In India, you can request a referral to a high-risk obstetrics specialist through your prescribing doctor or through a tertiary care hospital. Zelta's physician network can also help facilitate specialist consultations if needed.

If you are on semaglutide and considering pregnancy in the coming months or years, here is a practical framework for discussion with your doctor:

6 to 12 Months Before Planned Conception

• Inform your doctor about your pregnancy plans.
• Discuss whether to continue semaglutide, adjust the dose, or begin a transition plan.
• Review your current weight management and metabolic health goals in the context of pregnancy readiness.
• Ensure folic acid supplementation is in place (standard preconception care).

2 to 3 Months Before Planned Conception

• Discontinue semaglutide as recommended by your physician.
• Transition to alternative weight or blood sugar management strategies if needed.
• Use reliable contraception until the washout period is complete.
• Monitor for any changes in appetite, blood sugar, or weight during the transition.

During the Washout Period

• Stay in regular contact with your physician.
• Focus on nutrition, physical activity, and metabolic stability.
• Report any significant weight regain or blood sugar changes promptly.

After Conception

• Confirm pregnancy with your doctor.
• Transition fully to pregnancy-appropriate care, including obstetric monitoring.
• Do not restart semaglutide during pregnancy or breastfeeding without explicit medical guidance.

This timeline is a general guide. Your doctor may modify it based on your health conditions, the specific semaglutide product you use, and your individual response to discontinuation.

In India, semaglutide products are regulated by the Central Drugs Standard Control Organisation (CDSCO) under the Drug Controller General of India (DCGI). Patients should be aware of a few India-specific considerations:

• Not all semaglutide products available in India are identical. Some are branded imports (such as Ozempic), while others may be licensed generics or compounded preparations. The pregnancy-related warnings apply to the active molecule — semaglutide — regardless of the brand.
• Prescribing standards apply. Any physician prescribing semaglutide in India should discuss pregnancy risks as part of informed consent. If this was not discussed during your initial consultation, raise it proactively.
• Specialist referrals are available. Major hospitals in metropolitan areas such as Delhi, Mumbai, Bangalore, Chennai, and Hyderabad have endocrinology and high-risk obstetrics departments that can provide comprehensive preconception counselling for patients on GLP-1 medicines.
• Document your medication history. When you visit an obstetrician or fertility specialist, bring a complete list of all medications you have taken, including the dose and duration of semaglutide. This information is critical for accurate risk assessment.

The most important message of this entire article is simple: talk to your doctor about pregnancy before you conceive, not after.

Semaglutide is a powerful and effective medicine for weight management and type 2 diabetes. But like all medications, it has specific considerations around reproductive health that require planning and medical supervision.

If you are on semaglutide and pregnancy is anywhere in your future — even as a possibility — bring it up with your prescribing physician now. The earlier this conversation happens, the more options and flexibility you have.

At Zelta, our physicians are trained to discuss the full picture of GLP-1 treatment, including reproductive health planning. If you need guidance on transitioning off semaglutide safely or planning a pregnancy while managing your weight, book a consultation at zelta.in.

This article is for informational and educational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making any decisions about medication use during pregnancy or while planning to conceive. The information presented here is based on publicly available prescribing information and medical literature as of the date of publication. Individual circumstances vary, and treatment decisions should be made in consultation with your physician. GLP-1 medicines are prescription drugs and should only be used under medical supervision. Zelta facilitates consultations with licensed physicians — all treatment decisions are made by your doctor based on your individual health profile.